Groundbreaking RSV Vaccine Slashes Infant Hospitalizations by Up to 85%
New real-world data from England shows that RSV maternal vaccines significantly reduce hospital admissions for premature infants, offering critical protection.
In a major breakthrough for maternal and infant health, the largest real-world study conducted in England has confirmed that RSV (respiratory syncytial virus) vaccines for pregnant women can reduce hospital admissions for their premature babies by up to 85%. The findings, published in the prestigious medical journal The Lancet, provide compelling evidence of the transformative potential of these vaccines to safeguard vulnerable infants.
RSV is a common respiratory virus that typically causes mild, cold-like symptoms in adults and older children. However, for premature infants and those with underlying health conditions, RSV infections can lead to severe complications, such as bronchiolitis and pneumonia, often requiring hospitalization.
{{IMAGE_PLACEHOLDER}}Source: UK Government
